Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

Thierry Poynard(Pitié-Salpêtrière Hospital), Patrick Marcellin(Hôpital Beaujon), Samuel S. Lee(University of Calgary), Christian Niederau(Heinrich Heine University Düsseldorf), Gerald Minuk(University of Manitoba), G. Idéo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Vincent G. Bain(University of Alberta), Jenny Heathcote(Toronto General Hospital), Stefan Zeuzem(Goethe University Frankfurt), C. Trépo(Hôtel-Dieu de Lyon), Janice K. Albrecht
The Lancet
October 1, 1998
Cited by 2,332

Abstract


Related Papers

No related papers found

Powered by citation graph analysis